Application of Piperlongumine compounds for resisting platelet aggregation

Abstract

The invention relates to application of Piperlongumine compounds for resisting platelet aggregation, in particular to application of the Piperlongumine compounds which are used for preparing medicines and health care products for controlling thrombus or cardiovascular and cerebrovascular diseases. Experimental results indicate that the Piperlongumine compounds have remarkable effects on the platelet aggregation initiated by collagen, arachidonic acid and platelet activating factors, and the inhibition efficiency of the Piperlongumine compounds is superior to aspirin and also in a linear relationship with the compound concentration; thereby indicating that the Piperlongumine compounds have very wide prospects as a category of medicines or health care products for resisting the thrombus or controlling the cardiovascular and cerebrovascular diseases.

Description

technical field The present invention relates to a new application of traditional Chinese medicine components, in particular to the application of Piperamide compounds in anti-platelet aggregation. Background technique Cardiovascular and cerebrovascular diseases are one of the most serious diseases threatening human health in the world today, and its morbidity and mortality have surpassed tumors and ranked first in the world. According to the data released by the Ministry of Health of China in 2005, among the total mortality rate of the Chinese population, the mortality rate of cardiovascular and cerebrovascular diseases ranks first. The mortality rate of cerebrovascular diseases in urban residents is 21.2%, and the mortality rate of heart disease is 17.9%. The mortality rate of heart disease is 21.2%, and the mortality rate of heart disease is 11.8%. About 2.6 million people die of cardiovascular disease every year. Atherosclerosis, plaque rupture, and thrombus formation ...

AI Technical Summary

Problems solved by technology

But these drugs also have the same phenomenon similar to AR to varying degrees

On the other hand, the combination of two antiplatelet drugs will greatly increase the risk of severe bleeding in patients, so the combination of other antiplatelet drugs or alternative drugs is not an ideal method

Images